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LETTER
Response to: Letter to the Editor Regarding ‘‘An
Investigation of the Skin Barrier Restoring Effects
of a Cream and Lotion Containing Ceramides
in a Multi-Vesicular Emulsion in People with Dry,
Eczema-Prone, Skin: The RESTORE Study Phase1’’
Simon G. Danby . Paul V. Andrew . Kirsty Brown .
John Chittock . Linda J. Kay . Michael J. Cork
Received: August 23, 2021 / Published online: October 18, 2021
 The Author(s) 2021
Dear Editor,
We would like to respond to the points made
by Dr Rawlings and Dr Lane in their Letter to
the Editor regarding our paper entitled ‘‘An
investigation of the skin barrier restoring effects
of a cream and lotion containing ceramides in a
multi-vesicular emulsion in people with dry,
eczema-prone, skin: the RESTORE study
phase 1’’.
Firstly, we thank the authors for their inter-
est in our research and for providing this
opportunity to discuss the findings further. Six
points were raised which we will respond to in
turn below.
1. The authors question the lack of traditional
skin barrier measurements such as trans-
epidermal water loss (TEWL). The manu-
script clearly stated in the introduction that
‘‘Here we present the findings of the first
study in a program of work…’’ and ‘‘The aim
of this study was to determine the duration
of SCH [stratum corneum hydration]
imparted by the test products and compare
it with current ‘traditional’ moisturisers…’’.
The second study in the RESTORE program
of research explores the skin barrier enhanc-
ing effects of a 28-day regimen using the
test cream, and draws upon multiple tech-
niques including, but not limited to, TEWL.
The results of this second study are pre-
sented in a manuscript currently under
review for publication.
a. With respect to the wipe off measures
suggested, we are familiar with the
excellent work of Loden and colleagues
quoted, and acknowledge the impact
that residues left on the skin immedi-
ately after application can have [1, 2]. It
is for this reason that we leave a longer
than 2-h delay before taking the first
measurement to ensure that the pro-
duct is fully absorbed, and take the
precaution of removing visible residues
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where still present using a dry wipe
immediately prior to the 3-h time point.
The study by Loden and Lindberg
clearly shows that the effects of these
residues are short-lived [2]. Whilst we
recognise the different mechanisms of
hydration mentioned, it was not our
intention to discriminate between
them.
b. The authors suggest that ‘‘The skin
capacitance measures give the expected
hydration improvements… due to the
presence of glycerol in the products
based upon its dielectric constant’’. It is
correct that the corneometer is sensitive
to salts, and humectants/emollients in
products in addition to water. This
means that corneometer readings from
the sites treated with products contain-
ing these ingredients will indicate both
the increase in stratum corneum water
and the increase in salts and humec-
tants/emollients. As Crowther con-
cludes in his paper on the matter, skin
moisturization is based upon multiple
factors including an increase in salts
and humectants/emollients, which are
natural components of the skin neces-
sary to hold onto water (moisture) [3].
Moreover, capacitance measurements
directly correlate with clinical signs of
dryness. Nevertheless, we share the
authors’ caution over corneometer
measurements, and included visual skin
dryness scoring in this study and have
included additional measures of skin
water content in our second study [4].
Notably, we found a direct correlation
between corneometer readings and stra-
tum corneum water content deter-
mined spectroscopically despite the
potential interference from salts and
humectants in the test products on
corneometer measurements. What is
striking is that the reference products
in our study did not appreciably affect
capacitance. The authors agree that
such simple ‘‘paraffin-containing prod-
ucts give low capacitance
measurements’’, suggesting that they
do little to increase skin moisturization.
c. The authors appear to be suggesting
that different products should be tested
differently on the basis of the mecha-
nism of hydration. We suggest that it is
simply important to show which prod-
ucts impart greater increases in mois-
turization (irrespective of mechanism)
because these products rightly or
wrongly represent a single class of inter-
vention (emollients according to the
British National Formulary) for dry skin
conditions.
2. We kindly acknowledge the authors’
approval of our study cohort. The authors
also offer an excellent study reference mak-
ing use of the corneometer as a primary
outcome measure, and supporting its use in
cosmetic product claim substantiation with
respect to skin moisturization [5]. They
correctly identify that our corneometer
readings taken at the 12-h measurement
period after the single application of all of
the products tested suggest that the skin is
not moisturized enough to classify it as
normal [hydrated] skin. This, we would like
to point out, is consistent with the skin
dryness scores we also presented in the
manuscript. As we stated in the discussion,
‘‘The study is limited by its narrow focus on
moisturization potential after a single appli-
cation’’, and there is no reason to expect
that a single application alone is sufficient
to fully restore ‘normal’ skin moisturiza-
tion. ‘‘Our intention is to follow this pre-
liminary study with a vehicle-controlled
trial investigating the effects of a treatment
regimen with the TC [test cream] on skin
barrier structure and function, in a similar
population stratified by age.’’ We are puz-
zled by the suggestion that ‘‘a sustained
effect on skin hydration’’ can only be
claimed if normal skin hydration is
restored. We have been clear that the sus-
tained effect is an ‘increase in moisturiza-
tion’ and not restoration of hydration to a
level considered normal. Moreover, the
recent work by Draelos on the test lotion
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provides evidence of the additive effect of
regular applications over 4 weeks on skin
dryness. It also shows that the effect is
sustained for at least 48 h following cessa-
tion of treatment [6].
3. The authors are correct in their interpreta-
tion, which is consistent with our report.
4. The authors are right to correct the use of
nomenclature in this manuscript. We inad-
vertently provided both the old and new
nomenclature in different sections. For the
avoidance of doubt the test products con-
tained ceramide NP, ceramide AP, and
ceramide EOP-S. The Draelos study demon-
strates that stratum corneum ceramide
levels are increased following 28 days of
treatment with the test lotion [6]. As the
authors highlight, stratum corneum lipid
structure is a very important determinant of
skin barrier function, which is why we have
quantified the effects of the test cream on
this property in our second study, the
results of which are currently under review.
5. Whilst we provided evidence that the multi-
vesicular emulsion (MVE) technology can
control the release of a given substance, we
were not able to provide such for glycerol or
the skin lipids specifically. Accordingly, we
have not specifically attributed the effects
reported to this technology alone but
instead to the formulation as a whole as
appropriate, stating ‘‘…the combination of
glycerol and skin lipids in a MVE vehicle
significantly increase and prolong SCH
compared to traditional emollients without
these ingredients.’’ As a study of a finished
formulation, it is not possible to attribute
the effects to a single ingredient.
6. Many factors must be considered when
selecting a suitable reference product. Here
we set out to evaluate a finished formula-
tion (comprising multiple moisturizing
ingredients and a unique delivery system)
rather than a particular ingredient. Very
little is left of the formulation when the
moisturizing agents and emulsification/de-
livery system are removed. Simple paraffin
emollients make a reasonable substitute for
a vehicle in this case, but most importantly
they represent the most widely prescribed
competitor in the UK as explained in the
manuscript.
a. The authors offer evidence of the infe-
riority of the test products compared
with another glycerol-containing but
non-skin lipid/ceramide-containing
product in the form of a single figure in
a review article. The review provides no
detail on which to assess the design and
quality of the study and relies upon a
single outcome, skin conductance. But
as the authors have raised in their letter,
such skin measurements alone are not a
reliable measure of overall product
performance.
In summary, we have faithfully reported the
results of the study named above and specifi-
cally highlighted its limitations. We share the
authors’ view that multiple measures, including
measures of skin barrier structure and function,
are necessary to fully evaluate the performance
of moisturizers. With this in mind we encourage
you to read the results of the second and most
comprehensive part of the RESTORE program of
research when it is published.
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